Crispr Therapeutics AG Form 4 insider transactions

Director Katherine A. High acquired 13,000 stock options in CRISPR Therapeutics AG on May 30, 2024.

Director Harold Edward Fleming receives options to purchase 13,000 common shares of CRISPR Therapeutics.

Director Douglas A. Treco of CRISPR Therapeutics AG acquired 13,000 stock options on May 30, 2024, according to a recent SEC Form 4 filing.

Naimish Patel, Chief Medical Officer of CRISPR Therapeutics, was granted stock options for 85,000 shares and 40,000 restricted stock units on May 28, 2024.

Julianne Bruno, Chief Operating Officer of CRISPR Therapeutics AG, reports the acquisition of 20,000 restricted stock units on May 23, 2024, vesting in full on May 23, 2026.

CEO Samarth Kulkarni exercised stock options and sold CRISPR Therapeutics shares on April 15, 2024, according to a Form 4 filing with the SEC.

James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, received stock options for 33,333 common shares and 25,000 restricted stock units on March 20, 2024.

Raju Prasad, CFO of CRISPR Therapeutics, was granted stock options for 36,168 common shares and 25,000 restricted stock units on March 20, 2024.

CEO of CRISPR Therapeutics, Samarth Kulkarni, reports acquisition of stock options and restricted stock units.

Chief Financial Officer of CRISPR Therapeutics, Raju Prasad, sold shares to cover tax obligations following the vesting of restricted stock units.

CEO Samarth Kulkarni exercised stock options and sold CRISPR Therapeutics shares on March 15, 2024, according to a recent SEC filing.

James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

CEO Samarth Kulkarni reports acquisition and disposal of CRISPR Therapeutics shares and restricted stock units to cover tax obligations.

Director Simeon George reports the acquisition of CRISPR Therapeutics shares through several investment partnerships, disclaiming beneficial ownership except to the extent of his pecuniary interest.